DCT

1:26-cv-00401

Neurelis Inc v. Padagis LLC

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00401, D. Del., 04/08/2026
  • Venue Allegations: Plaintiff alleges venue is proper in the District of Delaware because Defendants Padagis LLC and Padagis US LLC are organized under the laws of Delaware and are subject to personal jurisdiction in the district. Venue over Padagis Israel is alleged on the basis that it is a non-resident defendant that may be sued in any judicial district.
  • Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's VALTOCO® (diazepam nasal spray) constitutes an act of infringement of a patent directed to a pharmaceutical formulation for intranasal drug delivery.
  • Technical Context: The technology relates to pharmaceutical compositions designed for the nasal administration of benzodiazepine drugs, such as diazepam, which are used for the acute treatment of seizures.
  • Key Procedural History: This action was initiated under the Hatch-Waxman Act following a notice letter from Padagis, dated March 12, 2026, which informed Neurelis of its ANDA filing containing a Paragraph IV certification against the asserted patent. The complaint notes this is one of several related actions between Neurelis and Padagis (as well as other generic manufacturers), suggesting a broader, ongoing multi-patent litigation campaign concerning the VALTOCO® product.

Case Timeline

Date Event
2008-03-28 U.S. Patent No. 12,521,400 Priority Date
2024-03-26 Padagis sends First Notice Letter to Neurelis regarding other patents
2024-05-08 Neurelis files "Padagis I Action"
2025-05-21 Padagis sends Second Notice Letter to Neurelis
2025-07-02 Neurelis files "Padagis II Action"
2025-09-02 Padagis sends Third Notice Letter to Neurelis
2025-10-03 Neurelis files "Padagis III Action"
2025-11-26 Neurelis files "Lupin I Action"
2026-01-13 U.S. Patent No. 12,521,400 Issued
2026-03-11 Neurelis files "Lupin II Action" and "Amneal I Action"
2026-03-12 Padagis sends Fourth Notice Letter to Neurelis regarding U.S. Patent No. 12,521,400
2026-04-08 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,521,400 - "Administration of Benzodiazepine Compositions"

  • Patent Identification: U.S. Patent No. 12,521,400, "Administration of Benzodiazepine Compositions", issued January 13, 2026 (the "'400 Patent").

The Invention Explained

  • Problem Addressed: The patent's background describes challenges with existing methods for administering benzodiazepine drugs to treat conditions like seizures '400 Patent, col. 1:40-45 Oral administration can be slow and subject to metabolic breakdown in the liver, potentially requiring larger doses '400 Patent, col. 2:1-6 Intravenous delivery is fast but impractical outside of a clinical setting, while suppository administration is inconvenient '400 Patent, col. 2:9-20 The central problem is the need for a delivery method that is both rapid and easily administered by a caregiver.
  • The Patented Solution: The invention is a pharmaceutical composition for nasal administration that dissolves a benzodiazepine drug, such as diazepam, in a carrier system comprising one or more tocopherols (Vitamin E) and one or more alcohols '400 Patent, abstract '400 Patent, col. 2:24-31 This formulation creates a stable solution that can be delivered as a nasal spray, providing a non-invasive and rapid-acting alternative to injections or oral tablets '400 Patent, col. 2:24-31 '400 Patent, col. 16:11-16
  • Technical Importance: This technology enables the creation of a "rescue medicine" for seizures that can be administered quickly by a non-professional caregiver, which is critical for treating intermittent, stereotypic episodes of frequent seizure activity outside of a hospital setting '400 Patent, col. 1:40-45

Key Claims at a Glance

  • The complaint asserts infringement of claims 1-21, with a focus on independent claim 1 '400 Patent, col. 37
  • Independent Claim 1 requires:
    • A pharmaceutical composition for intranasal administration comprising:
    • about 1 to about 20 mg of diazepam dissolved in
    • about 45% to about 85% (w/w) of one or more natural or synthetic tocopherols or tocotrienols selected from a specified group,
    • and about 25% to about 40% (w/w) of one or more alcohols selected from a specified group,
    • wherein the pharmaceutical composition is a solution of 50 µL to 150 µL,
    • and wherein the pharmaceutical composition is in a pharmaceutically-acceptable spray formulation for intranasal administration.
  • The complaint reserves the right to assert dependent claims '400 Patent, col. 37

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is the "Padagis ANDA Product," a generic version of VALTOCO® (diazepam nasal spray) for which Padagis seeks FDA approval under ANDA No. 219320 Compl. ¶1

Functionality and Market Context

  • The Padagis ANDA Product is described as a diazepam nasal spray, 10 mg/spray, intended for the same therapeutic use as Neurelis's branded VALTOCO® product Compl. ¶1 VALTOCO® is a prescription rescue medicine for the short-term treatment of seizure clusters in epilepsy patients Compl. ¶21 By filing an ANDA, Padagis seeks to market a generic version of this product prior to the expiration of the '400 Patent Compl. ¶1 The complaint alleges that upon approval, Padagis will commercially manufacture, use, and sell this product in the United States Compl. ¶40

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed claim chart or specific evidence of infringement, which is common in initial ANDA litigation complaints filed before discovery. The infringement theory is based on the allegation that the product described in Padagis's confidential ANDA filing will, upon approval and sale, meet all the limitations of the asserted claims Compl. ¶39

'400 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition for intranasal administration comprising: The Padagis ANDA Product is alleged to be a pharmaceutical composition for intranasal administration. ¶39 col. 2:24-26
about 1 to about 20 mg of diazepam... The Padagis ANDA Product is a 10 mg diazepam/spray, which is alleged to fall within the claimed range. ¶1; ¶38 col. 5:24-25
...dissolved in... The Padagis ANDA Product is alleged to contain diazepam dissolved in its carrier system. ¶39 col. 1:56-57
...about 45% to about 85% (w/w) of one or more natural or synthetic tocopherols or tocotrienols... The Padagis ANDA Product is alleged to contain tocopherols or tocotrienols within this weight-by-weight percentage range. ¶39 col. 3:2-4
...and about 25% to about 40% (w/w) of one or more alcohols... The Padagis ANDA Product is alleged to contain one or more alcohols within this weight-by-weight percentage range. ¶39 col. 3:10-14
...wherein the pharmaceutical composition is a solution of 50 µL to 150 µL... The Padagis ANDA Product is alleged to be a solution with a volume per spray within this range. ¶39 col. 33:16-19
...and wherein the pharmaceutical composition is in a pharmaceutically-acceptable spray formulation for intranasal administration. The Padagis ANDA Product is alleged to be a pharmaceutically-acceptable spray formulation for intranasal administration. ¶1; ¶39 col. 5:19-22
  • Identified Points of Contention:
    • Scope Questions: The primary dispute will likely center on the confidential details of the Padagis ANDA Product's formulation. A central question is whether the precise weight-by-weight percentages of its excipients fall within the ranges claimed in the '400 Patent, especially as interpreted through the term "about."
    • Technical Questions: A key technical question will be whether the diazepam in the accused product is fully "dissolved" to form a "solution," as required by the claim. The defense may argue that its product is a different formulation type, such as a micro-suspension or emulsion, which could place it outside the literal scope of the claim.

V. Key Claim Terms for Construction

  • The Term: "dissolved in" / "solution"

    • Context and Importance: This term is critical because it defines the physical state of the claimed composition. If the Padagis ANDA Product achieves its formulation through a suspension, emulsion, or other non-solution mechanism, it may not infringe. Practitioners may focus on this term because the patent specification discusses both solutions and particulate suspensions, suggesting a deliberate distinction '400 Patent, col. 2:40-46 '400 Patent, col. 8:30-33
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The complaint does not provide sufficient detail for analysis of evidence for a broader interpretation.
      • Evidence for a Narrower Interpretation: Claim 1 explicitly recites "diazepam dissolved in" the carrier and further requires that "the pharmaceutical composition is a solution." This dual requirement suggests the term should be given its plain and ordinary meaning of a homogenous mixture with no suspended particles. The specification also contrasts dissolved formulations with those containing "microparticles" or "nanoparticles," reinforcing that a "solution" is distinct from a suspension '400 Patent, col. 2:40-46

  • The Term: "about"

    • Context and Importance: This term modifies all numerical ranges in claim 1 (e.g., "about 1 to about 20 mg," "about 45% to about 85%"). The scope of "about" will be dispositive if the Padagis ANDA Product's formulation is close to, but not exactly within, the recited numerical boundaries.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The term "about" is generally understood to afford some degree of numerical flexibility to account for measurement uncertainty and minor, insignificant variations. The scope could be informed by what a person of ordinary skill in the art of pharmaceutical formulation would consider equivalent.
      • Evidence for a Narrower Interpretation: The patent provides numerous specific percentage ranges in the detailed description '400 Patent, col. 13:9-30 A defendant could argue that the specificity of these disclosed ranges limits the intended breadth of "about" in the claims.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon FDA approval, Padagis will actively induce infringement by marketing its ANDA Product and will contribute to infringement, which will occur when end-users administer the product Compl. ¶40 Knowledge and intent are inferred from Padagis's submission of the ANDA, which demonstrates knowledge of the patent and an intent to sell the accused product for the patented use Compl. ¶41
  • Willful Infringement: Willfulness is alleged based on Padagis having "full knowledge of the '400 patent and its claims" prior to the lawsuit, as evidenced by its submission of a Paragraph IV certification, and proceeding despite this knowledge Compl. ¶41

VII. Analyst's Conclusion: Key Questions for the Case

This case will likely hinge on the confidential technical details of the defendant's ANDA filing, which will be revealed during discovery. The central questions for the court appear to be:

  • A core issue will be one of formulation matching: Does the precise composition of the Padagis ANDA Product, as detailed in its confidential FDA submission, literally meet the specific weight-percentage and volume limitations recited in Claim 1 of the '400 patent?
  • A key definitional question will be one of physical state: Does the evidence show that the diazepam in the accused product is fully "dissolved" to form a true "solution" as required by the claim, or does it exist in a different physical state, such as a suspension, that would support a finding of non-infringement?
  • Finally, the dispute may turn on claim construction: How broadly will the court interpret the term "about" as it applies to the numerical ranges in the claims, and will that interpretation be wide enough to capture the defendant's formulation if it falls near the boundaries of the claimed ranges?
Loading Complaint